Breast cancer vaccine: analysis of potential therapeutic vaccines and effects

Jiayi Ji

doi:10.1117/12.2692643

7 September 2023 Breast cancer vaccine: analysis of potential therapeutic vaccines and effects

Jiayi Ji

Proceedings Volume 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023); 1278937 (2023) https://doi.org/10.1117/12.2692643
Event: International Conference on Modern Medicine and Global Health (ICMMGH 2023), 2023, Oxford, United Kingdom

Abstract

Many vaccinations have been developed for the prevention and treatment of cancer since the hepatitis B vaccine for liver cancer received approval as the first cancer vaccine. So far, three cancer vaccines have been approved by the FDA, but none of them is used to treat breast cancer. Scientific research focusing on the development of breast cancer vaccines had been an ongoing topic and several potential vaccine therapies have emerged. Globo-H is a suitable candidate for metastatic and triple negative breast cancer, which requires carrier protein or adjuvants conjugation induce antibody response against identified cancer antigen. Suitable adjuvant such as lipid-based carrier monophosphorylate lipid A (MPLA) is required for proper level of immune stimulation. Another large category of breast cancer vaccine is related to a commonly expressed receptor of the cancer cell’s surface: HER2/neu. E75 and GP2 directly target HERs and induce immune response for HLA A2/A3+ patients. AE37, on the other hands, is more potent for treating triple negative patients with low level of HER2 expression on cancer cells. AE37’s ability to induce T-cell immune response is related to structural conformation of MHC class II epitope driven by the linkage of li-Key-peptide, and it does not rely on high level of HER2 expression to induce T-cell mediated immune response. Overall, AE37 seems to be the most potential candidate for cancer vaccine, but its effectiveness does require further clinical trials to be proven.

Citation Download Citation

Jiayi Ji "Breast cancer vaccine: analysis of potential therapeutic vaccines and effects", Proc. SPIE 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023), 1278937 (7 September 2023); https://doi.org/10.1117/12.2692643

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available